231 related articles for article (PubMed ID: 27226593)
21. The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs.
Greig GM; Francis DA; Falgueyret JP; Ouellet M; Percival MD; Roy P; Bayly C; Mancini JA; O'Neill GP
Mol Pharmacol; 1997 Nov; 52(5):829-38. PubMed ID: 9351974
[TBL] [Abstract][Full Text] [Related]
22. Competition and allostery govern substrate selectivity of cyclooxygenase-2.
Mitchener MM; Hermanson DJ; Shockley EM; Brown HA; Lindsley CW; Reese J; Rouzer CA; Lopez CF; Marnett LJ
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12366-71. PubMed ID: 26392530
[TBL] [Abstract][Full Text] [Related]
23. Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib.
Blobaum AL; Marnett LJ
J Biol Chem; 2007 Jun; 282(22):16379-90. PubMed ID: 17434872
[TBL] [Abstract][Full Text] [Related]
24. Fatty Acid Binding to the Allosteric Subunit of Cyclooxygenase-2 Relieves a Tonic Inhibition of the Catalytic Subunit.
Dong L; Yuan C; Orlando BJ; Malkowski MG; Smith WL
J Biol Chem; 2016 Dec; 291(49):25641-25655. PubMed ID: 27756840
[TBL] [Abstract][Full Text] [Related]
25. Dual cyclooxygenase-fatty acid amide hydrolase inhibitor exploits novel binding interactions in the cyclooxygenase active site.
Goodman MC; Xu S; Rouzer CA; Banerjee S; Ghebreselasie K; Migliore M; Piomelli D; Marnett LJ
J Biol Chem; 2018 Mar; 293(9):3028-3038. PubMed ID: 29326169
[TBL] [Abstract][Full Text] [Related]
26. Fluorescent indomethacin-dansyl conjugates utilize the membrane-binding domain of cyclooxygenase-2 to block the opening to the active site.
Xu S; Uddin MJ; Banerjee S; Duggan K; Musee J; Kiefer JR; Ghebreselasie K; Rouzer CA; Marnett LJ
J Biol Chem; 2019 May; 294(22):8690-8698. PubMed ID: 31000626
[TBL] [Abstract][Full Text] [Related]
27. Multiple actions of fenamates and other nonsteroidal anti-inflammatory drugs on GABA
Mansikkamäki S; Sinkkonen ST; Korpi ER; Lüddens H
Eur J Pharmacol; 2019 Jun; 853():247-255. PubMed ID: 30930251
[TBL] [Abstract][Full Text] [Related]
28. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium.
Waterbury LD; Silliman D; Jolas T
Curr Med Res Opin; 2006 Jun; 22(6):1133-40. PubMed ID: 16846546
[TBL] [Abstract][Full Text] [Related]
29. Assay of Endocannabinoid Oxidation by Cyclooxygenase-2.
Kudalkar SN; Kingsley PJ; Marnett LJ
Methods Mol Biol; 2016; 1412():205-15. PubMed ID: 27245906
[TBL] [Abstract][Full Text] [Related]
30. Cyclooxygenase-2 catalysis and inhibition in lipid bilayer nanodiscs.
Orlando BJ; McDougle DR; Lucido MJ; Eng ET; Graham LA; Schneider C; Stokes DL; Das A; Malkowski MG
Arch Biochem Biophys; 2014 Mar; 546():33-40. PubMed ID: 24503478
[TBL] [Abstract][Full Text] [Related]
31. Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors.
Zarghi A; Kakhgi S; Hadipoor A; Daraee B; Dadrass OG; Hedayati M
Bioorg Med Chem Lett; 2008 Feb; 18(4):1336-9. PubMed ID: 18226898
[TBL] [Abstract][Full Text] [Related]
32. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
33. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond.
Rao P; Knaus EE
J Pharm Pharm Sci; 2008 Sep; 11(2):81s-110s. PubMed ID: 19203472
[TBL] [Abstract][Full Text] [Related]
34. Molecular dynamics simulations of arachidonic acid complexes with COX-1 and COX-2: insights into equilibrium behavior.
Furse KE; Pratt DA; Porter NA; Lybrand TP
Biochemistry; 2006 Mar; 45(10):3189-205. PubMed ID: 16519514
[TBL] [Abstract][Full Text] [Related]
35. Structure-based QSAR study on differential inhibition of human prostaglandin endoperoxide H synthase-2 (COX-2) by nonsteroidal anti-inflammatory drugs.
Pouplana R; Lozano JJ; Pérez C; Ruiz J
J Comput Aided Mol Des; 2002 Oct; 16(10):683-709. PubMed ID: 12650588
[TBL] [Abstract][Full Text] [Related]
36. Role of Tyr348 in Tyr385 radical dynamics and cyclooxygenase inhibitor interactions in prostaglandin H synthase-2.
Rogge CE; Ho B; Liu W; Kulmacz RJ; Tsai AL
Biochemistry; 2006 Jan; 45(2):523-32. PubMed ID: 16401081
[TBL] [Abstract][Full Text] [Related]
37. Surface plasmon resonance studies and biochemical evaluation of a potent peptide inhibitor against cyclooxygenase-2 as an anti-inflammatory agent.
Somvanshi RK; Kumar A; Kant S; Gupta D; Singh SB; Das U; Srinivasan A; Singh TP; Dey S
Biochem Biophys Res Commun; 2007 Sep; 361(1):37-42. PubMed ID: 17640617
[TBL] [Abstract][Full Text] [Related]
38. Redox-cycling and intercalating properties of novel mixed copper(II) complexes with non-steroidal anti-inflammatory drugs tolfenamic, mefenamic and flufenamic acids and phenanthroline functionality: Structure, SOD-mimetic activity, interaction with albumin, DNA damage study and anticancer activity.
Simunkova M; Lauro P; Jomova K; Hudecova L; Danko M; Alwasel S; Alhazza IM; Rajcaniova S; Kozovska Z; Kucerova L; Moncol J; Svorc L; Valko M
J Inorg Biochem; 2019 May; 194():97-113. PubMed ID: 30849593
[TBL] [Abstract][Full Text] [Related]
39. Structural basis for selective inhibition of COX-2 by nimesulide.
Fabiola GF; Pattabhi V; Nagarajan K
Bioorg Med Chem; 1998 Dec; 6(12):2337-44. PubMed ID: 9925294
[TBL] [Abstract][Full Text] [Related]
40. Partnering between monomers of cyclooxygenase-2 homodimers.
Yuan C; Rieke CJ; Rimon G; Wingerd BA; Smith WL
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6142-7. PubMed ID: 16606823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
